GeneDx Study Validates Hospital-Wide Rapid Genomic Sequencing for Pediatric Care — GeneDx Holdings Corp.

Event summary

GeneDx and Seattle Children’s published a study in Genetics in Medicine demonstrating the benefits of rapid genome sequencing (rGS) across all pediatric inpatient units, not just intensive care.
The study evaluated over 1,000 pediatric inpatients over 3.5 years, showing a 35% overall diagnostic yield, with 43% in non-ICU wards.
Highest diagnostic yield (63%) was observed in children with faltering growth, identifying 37 distinct genetic diagnoses.
Hospital-wide rGS implementation reduced outpatient genetics wait times and eliminated race-based disparities in access to testing.

The big picture

The study challenges the traditional view that rapid genome sequencing is only beneficial for critically ill infants in intensive care units. By demonstrating its value across all pediatric inpatient settings, GeneDx and Seattle Children’s are positioning rGS as a standard tool for earlier genetic diagnosis and improved clinical management. This shift could significantly expand the market for genomic testing and reshape how hospitals approach pediatric care.

What we're watching

Adoption Pace: How quickly other pediatric hospitals will adopt hospital-wide rGS based on these findings.
Operational Impact: Whether the operational benefits, such as reduced wait times and improved equity, will drive broader health system adoption.
Market Expansion: The pace at which GeneDx can scale this model to other hospital systems and patient populations.